Crinetics Announces May 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces May 2023 inducement grants: the stock options were granted as inducements material to nine employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update


Crinetics Pharmaceuticals reported financial results and provided an update on first quarter 2023 clinical progress

Crinetics Announces April 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces April 2023 inducement grants: the stock options were granted as inducements material to 15 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Announces March 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces March 2023 inducement grants: the stock options were granted as inducements material to eight employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Reports Fourth Quarter and Full Year 2022 Financial Results


Crinetics Pharmaceuticals reported financial results for the fourth quarter and year ended December 31, 2022